Limiting Carbohydrates Could Reduce Breast Cancer Recurrence in Women with Positive IGF1 Receptor
Article ID: 619108
Released: 11-Jun-2014 8:00 AM EDT
Source Newsroom: Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center
Newswise — (Lebanon, NH, 6/11/14) Dartmouth researchers have found that reducing carbohydrate intake could reduce the risk of breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor. The study, “Risk of Breast Cancer Recurrence Associated with Carbohydrate Intake and Tissue Expression of IGFI Receptor,” will appear in the July issue of Cancer Epidemiology Biomarkers & Prevention.
“There is a growing body of research demonstrating associations between obesity, diabetes, and cancer risk,” said lead author Jennifer A. Emond, an instructor in the Department of Community and Family Medicine at the Geisel School of Medicine at Dartmouth College. “There are similarities between the biological pathways that underlie all of these conditions, and there is some evidence to suggest that over-activation of the insulin/insulin-like growth factor axis, which increases the availability of IGF1 in the blood, may relate to a poor prognosis among breast cancer survivors.”
Receptors for IGF1 have been found in breast tumor tissue, and expression of those receptors may contribute to treatment resistance among breast cancer survivors. Since diet can influence insulin activation, the researchers wondered whether diet could impact breast cancer prognosis based on expression of the IGF1 receptor in the primary breast tumor tissue.
Using an unusual approach, this study assessed the combined association of two factors implicated in tumor growth—carbohydrate intake and IGF1 receptor status—to test whether activating the insulin/insulin-like growth-factor axis can impact breast cancer. Since carbohydrates stimulate the biological pathway that can increase concentrations of IGF1, the researchers focused on carbohydrate intake. The women they studied were part of a larger intervention trial called the Women’s Healthy Eating and Living (WHEL) study conducted between 2001 and 2007.
“We found an association between increased breast cancer recurrence in women with a primary breast cancer tumor that was positive for the IGF1 receptor, which is consistent with other studies,” said Emond. “We further found that a decreased carbohydrate intake was associated with decreased breast cancer recurrence for these women.”
This is the first study to suggest that it might be possible to personalize recommended diets for breast cancer survivors based on the molecular characteristics of their primary tumor. Further research is needed to confirm these findings, and Emond notes that breast cancer survivors should not be concerned about dramatically lowering their carbohydrate intake based on this study.
“There are still many unanswered questions regarding this study, including what type of carbohydrate-containing foods may be the most important foods that breast cancer survivors should limit,” she said. “Breast cancer survivors should continue to follow a plant-based dietary pattern as suggested by the American Association for Cancer Research and the American Cancer Association, which means eating lots of fiber rich vegetables, legumes, and fruits; consuming whole grains and also limiting refined grains, starchy vegetables, and added sugar.”
Co-authors on the study are: Jennifer A. Emond , John P. Pierce , Loki Natarajan , Laarni R. Gapuz , John Nguyen , Barbara A. Parker , Nissi M. Varki, and Ruth E. Patterson. J.P. Pierce, B.A. Parker, L. Natarajan, and J.A. Emond were funded by a donation from the Walton Family Foundation, from National Cancer Institute (CA-69375), and the General Clinical Research Centers, NIH (M01-RR00070, M01-RR00079, and M01-RR00827). J.A. Emond was supported by an Institutional training grant from the National Institute of General Medical Sciences (5 T32-GM084896) and the National Cancer Institute Centers for Transdisciplinary Research on Energetics and Cancer (1U54CA155435-01). L. Natarajan was also partially funded by National Cancer Institute (1R01CA166293-01A1). Finally, J.A. Emond and J.P. Pierce received funding from Ms. Carol Vassiliadis and her family in the form of philanthropic support for these analyses.
About Norris Cotton Cancer Center at Dartmouth-Hitchcock Norris Cotton Cancer Center combines advanced cancer research at Dartmouth and the Geisel School of Medicine with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute’s “Comprehensive Cancer Center” designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.
# 30 #